Glioblastoma Clinical Trials

75 studies are recruiting for glioblastoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 3

1. CUE-102 in Recurrent Glioblastoma

   The goal of this study is to evaluate the safety of the experimental drug, CUE-102, and establish the recommended dose of CUE-102 for participants with Recurrent Glioblastoma (GBM). The name of the study drug involved in this study is: -CUE-102 (a type of fusion protein)

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Dana Farber Cancer Institute, Boston, Massachusetts

   Locations

   2 in total

   Run by

   David Reardon, MD

   See if you can join NCT06917885 on ClinicalTrials.gov

2. Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer

   The purpose of this study is to find out how much tratuzumab deruxtecan (T-DXd) can penetrate the tumor when injected into the body, and whether T-DXd may be an effective treatment for brain cancers that express the HER2 protein.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT06058988 on ClinicalTrials.gov

3. Evaluation of the CONVIVO System

   The primary objective of this study is to evaluate the diagnostic performance of the CONVIVO confocal endomicroscope in discriminating between normal and abnormal tissue in vivo during brain tumor surgery. The interpretation of intraoperative images obtained in situ will be tested against conventio…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire

   Run by

   Dartmouth-Hitchcock Medical Center

   See if you can join NCT05139277 on ClinicalTrials.gov

4. Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue

   To collect and preserve glioblastoma tissue during standard of care tumor resection surgery and blood for future molecular and genetic testing. Tissue for research will be collected from three different regions within the same tumor to study how these regions differ in their structure, DNA, and RNA…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Miami Cancer Institute at Baptist Health, Inc., Miami, Florida

   Run by

   Baptist Health South Florida

   See if you can join NCT05756985 on ClinicalTrials.gov

5. Venous Thromboembolism Prevention in Outpatients With Glioma

   This is an open label study of apixaban for venous thromboembolism prevention in patients with newly diagnosed grade 4 glioma.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Vermont Medical Center, Burlington, Vermont

   Run by

   University of Vermont Medical Center

   See if you can join NCT05683808 on ClinicalTrials.gov

6. Key Longitudinal Associations With Risk and Glioblastoma Outcomes

   The goal of this observational study is to find out what factors affect the health and risks in adults with glioblastoma (GBM), a grade 4 brain cancer. The main questions it aims to answer are: * How do genetic and immune system factors impact survival and quality of life in GBM patients? * What oc…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Duke University, Durham, North Carolina

   Run by

   Duke University

   See if you can join NCT06625684 on ClinicalTrials.gov

7. Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer

   Recent lab-based discoveries suggest that IDO (indoleamine 2,3-dioxygenase) and BTK (Bruton's tyrosine Kinase) form a closely linked metabolic checkpoint in tumor-associated antigen-presenting cells. The central clinical hypothesis for the GCC2020 study is that combining ibrutinib (BTK-inhibitor) w…

   Stage

   Phase 1

   Ages

   3 to 25

   Site

   Augusta University, Georgia Cancer Center, Augusta, Georgia

   Run by

   Theodore S. Johnson

   See if you can join NCT05106296 on ClinicalTrials.gov

8. Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

   The primary objective of this Phase 1, open-label, dose-escalation, and exploratory study is to evaluate the safety and tolerability profile (establish the maximum-tolerated dose) and evaluate the occurrence of dose-limiting toxicities (DLTs) following single weekly or multiple-day weekly dose regi…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   National Institutes of Health, Bethesda, Maryland

   Run by

   Jazz Pharmaceuticals

   See if you can join NCT04541082 on ClinicalTrials.gov

9. Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.

   The primary goal of this Phase I study is to determine the maximum tolerated dose of oncolytic adenovirus mediated double suicide-gene therapy in combination with fractionated stereotactic radiosurgery in patients with recurrent high-grade astrocytoma undergoing resection.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Henry Ford Health System, Detroit, Michigan

   Run by

   Henry Ford Health System

   See if you can join NCT05686798 on ClinicalTrials.gov

10. A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions

    This study will administer the investigational drug, BDTX-1535 to eligible patients with recurrent high-grade glioma (HGG) and newly-diagnosed glioblastoma (nGBM). BDTX-1535 was designed to block a growth signal important to some cancers. BDTX-1535 is being tested in this study to see if it can be …

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    Chandler Regional Medical Center, Chandler, Arizona

    Locations

    2 in total

    Run by

    St. Joseph's Hospital and Medical Center, Phoenix

    See if you can join NCT06072586 on ClinicalTrials.gov

11. Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma

    This clinical trial uses a type of imaging scan called magnetic resonance imaging (MRI) to study brain tumor biology in patients with glioblastoma that can be removed by surgery (resectable). Malignant gliomas are the second leading cause of cancer mortality in people under the age of 35 in the Uni…

    Stage

    Not phased

    Ages

    18 and older

    Site

    UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

    Run by

    Jonsson Comprehensive Cancer Center

    See if you can join NCT06090903 on ClinicalTrials.gov

12. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage

    Not phased

    Ages

    Any age

    Site

    Massive Bio SYNERGY-AI site, Birmingham, Alabama

    Locations

    68 in total

    Run by

    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

13. Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma

    This is a phase 1 study evaluating the safety and feasibility of laser interstitial thermal therapy (LITT) followed by lomustine (CCNU) for recurrent glioblastoma in adults. The primary aim is to evaluate the safety of the combination of LITT plus lomustine based on the assessment of treatment-rela…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California Davis Comprehensive Cancer Center, Sacramento, California

    Run by

    University of California, Davis

    See if you can join NCT07145112 on ClinicalTrials.gov

14. A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma

    This research study is studying troriluzole as a possible treatment for recurrent glioblastoma. The name of the study drug involved in this research study is: -Troriluzole (a tripeptide prodrug of riluzole)

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    Brigham and Women's Hospital, Boston, Massachusetts

    Locations

    3 in total

    Run by

    Ugonma Chukwueke

    See if you can join NCT06552260 on ClinicalTrials.gov

15. Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma

    This study is designed as a single center, prospective, open label, single-arm therapeutic trial with both surgical and non-surgical cohorts.

    Stage

    Phase 2

    Ages

    Any age

    Site

    Mays Cancer Center, UT Health San Antonio, San Antonio, Texas

    Run by

    The University of Texas Health Science Center at San Antonio

    See if you can join NCT04863950 on ClinicalTrials.gov

16. Implantable Microdevice In Primary Brain Tumors

    This pilot study will assess the safety and feasibility of using an implantable microdevice to measure local intratumor response to chemotherapy and other clinically relevant drugs in malignant brain tumors. * The device involved in this study is called a microdevice. * The drugs used in this study…

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    Brigham and Women's Hospital, Boston, Massachusetts

    Run by

    Oliver Jonas

    See if you can join NCT04135807 on ClinicalTrials.gov

17. Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma

    The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma or astrocytoma is newly diagnosed, and to evaluate safety and tolerability of this combination at that dose.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Henry Ford Hospital, Detroit, Michigan

    Locations

    8 in total

    Run by

    Orbus Therapeutics, Inc.

    See if you can join NCT05879367 on ClinicalTrials.gov

18. Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma

    This phase I/II trial studies the side effects and best dose of Visudyne (liposomal verteporfin) and to see how well it works in treating patients with high grade EGFR-mutated glioblastoma that has come back (recurrent). Visudyne is FDA approved in combination with light to treat eye diseases. In t…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia

    Run by

    Emory University

    See if you can join NCT04590664 on ClinicalTrials.gov

19. Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas

    The objective of this study is to assess the tolerability, safety, and efficacy of Liposomal Curcumin (LC) in combination with radiotherapy (RT) and Temozolomide (TMZ) in patients with newly diagnosed High-Grade Gliomas (HGG).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sibley Memorial Hospital, Washington D.C., District of Columbia

    Locations

    2 in total

    Run by

    SignPath Pharma, Inc.

    See if you can join NCT05768919 on ClinicalTrials.gov

20. The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)

    Previous evidence has indicated that resection for recurrent glioblastoma might benefit the prognosis of these patients in terms of overall survival. However, the demonstrated safety profile of this approach is contradictory in the literature and the specific benefits in distinct clinical and molec…

    Stage

    Not phased

    Ages

    18 to 90

    Site

    University of California, San Francisco, San Francisco, California

    Locations

    8 in total

    Run by

    Jasper Gerritsen

    See if you can join NCT06283927 on ClinicalTrials.gov

21. The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)

    A greater extent of resection of the contrast-enhancing (CE) tumor part has been associated with improved outcomes in high-grade glioma patients. Recent results suggest that resection of the non-contrast-enhancing (NCE) part might yield even better survival outcomes (supramaximal resection, SMR). T…

    Stage

    Not phased

    Ages

    18 to 90

    Site

    University of California, San Francisco (UCSF), San Francisco, California

    Locations

    8 in total

    Run by

    Jasper Gerritsen

    See if you can join NCT06118723 on ClinicalTrials.gov

22. The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma

    Resection of glioblastoma in or near functional brain tissue is challenging because of the proximity of important structures to the tumor site. To pursue maximal resection in a safe manner, mapping methods have been developed to test for motor and language function during the operation. Previous ev…

    Stage

    Not phased

    Ages

    Up to 90

    Site

    University of California, San Francisco, San Francisco, California

    Locations

    8 in total

    Run by

    Erasmus Medical Center

    See if you can join NCT06273176 on ClinicalTrials.gov

23. The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)

    There are no guidelines or prospective studies defining the optimal surgical treatment for gliomas of older patients (≥70 years) or those with limited functioning performance at presentation (KPS ≤70). Therefore, the decision between resection and biopsy is varied, amongst neurosurgeons internation…

    Stage

    Not phased

    Ages

    18 to 90

    Site

    University of California, San Francisco, San Francisco, California

    Locations

    8 in total

    Run by

    Jasper Gerritsen

    See if you can join NCT06146725 on ClinicalTrials.gov

24. The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)

    There is no consensus on the optimal treatment of patients with high-grade glioma, especially when patients have limited functioning performance at presentation (KPS ≤70). Therefore, there are varied practice patterns around pursuing biopsy, resection, or palliation (best supportive care). This stu…

    Stage

    Not phased

    Ages

    18 to 90

    Site

    University of California, San Francisco, San Francisco, California

    Locations

    8 in total

    Run by

    Jasper Gerritsen

    See if you can join NCT06146738 on ClinicalTrials.gov

25. The PROGRAM-study: Awake Mapping Versus Asleep Mapping Versus No Mapping for Glioblastoma Resections

    The study is designed as an international, multicenter prospective cohort study. Patients with presumed glioblastoma (GBM) in- or near eloquent areas on diagnostic MRI will be selected by neurosurgeons. Patients will be treated following one of three study arms: 1) a craniotomy where the resection …

    Stage

    Not phased

    Ages

    18 to 90

    Site

    Erasmus MC, Rotterdam, South Holland

    Locations

    8 in total

    Run by

    Erasmus Medical Center

    See if you can join NCT04708171 on ClinicalTrials.gov